For many breast cancer patients, the conclusion of active treatment—chemotherapy, radiation, or surgery—is often viewed as a...
Oklahoma City, OK – In a significant stride towards understanding and potentially conquering one of the most...
California-based biopharmaceutical company Alumis has unveiled compelling Phase III clinical trial data for its novel TYK2 inhibitor,...
By Douglas Feil, NBCF Chief Program Officer In recent years, Glucagon-Like Peptide-1 (GLP-1) receptor agonists have surged...
NEW YORK, NY — As the sun sets on October 13, 2026, the global skyline will undergo...
The landscape of HER2-positive metastatic breast cancer treatment has undergone a significant transformation with the recent U.S....
The transition from active cancer treatment to survivorship is often described by patients as one of the...
AMMAN, JORDAN — The Director-General of the World Health Organization (WHO), Dr. Tedros Adhanom Ghebreyesus, has concluded...
The biotechnology sector continues to navigate a complex landscape defined by high-stakes clinical data, evolving regulatory standards,...
In a move that underscores the intensifying battle for dominance in the rapidly expanding electrophysiology market, Boston...
